References
- DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
- CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
- Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
- HoogendoornMHoogenveenRTRutten-van MolkenMPVestboJFeenstraTLCase-fatality of COPD exacerbations: a meta-analysis and statistical modeling approachEur Respir J201137350851520595157
- MiravitllesMFerrerMPontAZalacainREffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax200459538739515115864
- SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575141814229603117
- SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on deterioration of health status in COPDEur Respir J200423569870215176682
- AnderssonFBorgSJanssonSAThe costs of exacerbations in chronic obstructive pulmonary disease (COPD)Respir Med200296970070812243316
- OostenbrinkJBRutten-van MolkenMPResource use and risk factors in high-cost exacerbations of COPDRespir Med200498988389115338802
- O’ReillyJFWilliamsAERiceLHealth status impairment and costs associated with COPD exacerbation managed in hospitalInt J Clin Pract20076171112112017577296
- Global Initiative for chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2013
- CrinerGJBourbeauJDiekemperRLPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society GuidelineChest2015147489494225321320
- HoogendoornMFeenstraTLAsukaiYPatient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine?Value Health201619680081027712708
- HurstJRVestboJAnzuetoAEvaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
- BeehKMGlaabTStowasserSCharacterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialRespir Res201314111624168767
- BriggsASpencerMWangHManninoDSinDDDevelopment and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseArch Intern Med20081681717918195198
- MakeBJErikssonGCalverleyPMA score to predict short-term risk of COPD exacerbations (SCOPEX)Int J Chron Obstruct Pulmon Dis20151020120925670896
- NiewoehnerDELokhnyginaYRiceKRisk indexes for exacerbations and hospitalizations due to COPDChest20071311202817218552
- JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
- BertensLCReitsmaJBMoonsKGDevelopment and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2013849349924143086
- MullerovaHShuklaAHawkinsAQuintJRisk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort studyBMJ Open2014412e006171
- McGarveyLLeeAJRobertsJGruffydd-JonesKMcKnightEHaughneyJCharacterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care populationRespir Med2015109222823725613107
- HoogendoornMFeenstraTLAsukaiYCost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosValue Health201417552553625128045
- ReganEAHokansonJEMurphyJRGenetic epidemiology of COPD (COPDGene) study designCOPD201071324320214461
- MontnemeryPAdelrothEHeumanKPrevalence of obstructive lung diseases and respiratory symptoms in southern SwedenRespir Med199892121337134510197227
- KruisALBolandMRSchoonveldeCHRECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary careBMC Pulm Med20131311723522095
- VestboJAndersonWCoxsonHOECLIPSE investigatorsEvaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)Eur Respir J200831486987318216052
- DecramerMCelliBTashkinDPClinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trialCOPD20041230331217136995
- KeeneONCalverleyPMJonesPWVestboJAndersonJAStatistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisitedEur Respir J2008321172418591336
- Al-aniSSpigtMHofsetPMelbyeHPredictors of exacerbations of asthma and COPD during one year in primary careFam Pract201330662162824115012
- HuseboGRBakkePSAanerudMPredictors of exacerbations in chronic obstructive pulmonary disease: results from the Bergen COPD cohort studyPLoS One2014910e10972125279458
- KilicHKokturkNSariGCakirMDo females behave differently in COPD exacerbation?Int J Chron Obstruct Pulmon Dis20151082383025977604
- OwensGMGender differences in health care expenditures, resource utilization, and quality of careJ Manag Care Pharm20081432618439060
- KerkhofMFreemanDJonesRChisholmAPriceDBEffectiveness GroupPredicting frequent COPD exacerbations using primary care dataInt J Chron Obstruct Pulmon Dis2015102439245026609229